The spectrum of latent tuberculosis: rethinking the biology and intervention strategies
暂无分享,去创建一个
J. Flynn | R. Wilkinson | D. Schnappinger | T. Dick | C. Barry | V. Dartois | S. Ehrt | H. Boshoff | D. Young
[1] T. Dick,et al. Tuberculosis drug discovery: issues, gaps and the way forward. , 2009 .
[2] JoAnne L. Flynn,et al. Quantitative Comparison of Active and Latent Tuberculosis in the Cynomolgus Macaque Model , 2009, Infection and Immunity.
[3] Robert J Wilkinson,et al. Eliminating latent tuberculosis. , 2009, Trends in microbiology.
[4] J. Christian J. Ray,et al. Synergy between Individual TNF-Dependent Functions Determines Granuloma Performance for Controlling Mycobacterium tuberculosis Infection1 , 2009, The Journal of Immunology.
[5] Alimuddin Zumla,et al. Biomarkers for tuberculosis disease activity, cure, and relapse. , 2009, The Lancet. Infectious diseases.
[6] Sabine Ehrt,et al. Improved tetracycline repressors for gene silencing in mycobacteria , 2009, Nucleic acids research.
[7] P. Selzer. Antiparasitic and antibacterial drug discovery : from molecular targets to drug candidates , 2009 .
[8] Y. Manabe,et al. Tuberculosis genes expressed during persistence and reactivation in the resistant rabbit model. , 2009, Tuberculosis.
[9] M. Daly,et al. Multigenic control of tuberculosis resistance: analysis of a QTL on mouse chromosome 7 and its synergism with sst1 , 2009, Genes and Immunity.
[10] W. Bishai,et al. Role of the dosR-dosS Two-Component Regulatory System in Mycobacterium tuberculosis Virulence in Three Animal Models , 2008, Infection and Immunity.
[11] Mark J. Schreiber,et al. Peptide deformylase inhibitors of Mycobacterium tuberculosis: synthesis, structural investigations, and biological results. , 2008, Bioorganic & medicinal chemistry letters.
[12] Pilho Kim,et al. PA-824 Kills Nonreplicating Mycobacterium tuberculosis by Intracellular NO Release , 2008, Science.
[13] J. Collins,et al. Mistranslation of Membrane Proteins and Two-Component System Activation Trigger Antibiotic-Mediated Cell Death , 2008, Cell.
[14] S. Booker. Faculty Opinions recommendation of Biosynthesis and recycling of nicotinamide cofactors in mycobacterium tuberculosis. An essential role for NAD in nonreplicating bacilli. , 2008 .
[15] Thomas Dick,et al. The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis , 2008, Proceedings of the National Academy of Sciences.
[16] Madhukar Pai,et al. Systematic Review: T-Cellbased Assays for the Diagnosis of Latent Tuberculosis Infection: An Update , 2008, Annals of Internal Medicine.
[17] K. Higuchi,et al. Interferon‐γ responses after isoniazid chemotherapy for latent tuberculosis , 2008, Respirology.
[18] W. Bishai,et al. The aerosol rabbit model of TB latency, reactivation and immune reconstitution inflammatory syndrome. , 2008, Tuberculosis.
[19] C. Senner,et al. Cytological and Transcript Analyses Reveal Fat and Lazy Persister-Like Bacilli in Tuberculous Sputum , 2008, PLoS medicine.
[20] James A. Raleigh,et al. Tuberculous Granulomas Are Hypoxic in Guinea Pigs, Rabbits, and Nonhuman Primates , 2008, Infection and Immunity.
[21] Tige R. Rustad,et al. The Enduring Hypoxic Response of Mycobacterium tuberculosis , 2008, PloS one.
[22] Philip D. Butcher,et al. Probing Host Pathogen Cross-Talk by Transcriptional Profiling of Both Mycobacterium tuberculosis and Infected Human Dendritic Cells and Macrophages , 2008, PloS one.
[23] T. Shim,et al. Evaluation of Therapeutic Response of Tuberculoma Using F-18 FDG Positron Emission Tomography , 2008, Clinical nuclear medicine.
[24] Christopher Dye,et al. Eliminating human tuberculosis in the twenty-first century , 2008, Journal of The Royal Society Interface.
[25] Chris Abell,et al. Fragment-based approaches to enzyme inhibition. , 2007, Current opinion in biotechnology.
[26] W. Hillen,et al. In vivo gene silencing identifies the Mycobacterium tuberculosis proteasome as essential for the bacteria to persist in mice , 2007, Nature Medicine.
[27] D. Russell,et al. Mycobacterium tuberculosis invasion of macrophages: linking bacterial gene expression to environmental cues. , 2007, Cell host & microbe.
[28] G. Terstappen,et al. Target deconvolution strategies in drug discovery , 2007, Nature Reviews Drug Discovery.
[29] R. Lange,et al. The targets of currently used antibacterial agents: lessons for drug discovery. , 2007, Current pharmaceutical design.
[30] J. Collins,et al. A Common Mechanism of Cellular Death Induced by Bactericidal Antibiotics , 2007, Cell.
[31] John Chan,et al. Differences in Reactivation of Tuberculosis Induced from Anti-TNF Treatments Are Based on Bioavailability in Granulomatous Tissue , 2007, PLoS Comput. Biol..
[32] S. Klamt,et al. GSMN-TB: a web-based genome-scale network model of Mycobacterium tuberculosis metabolism , 2007, Genome Biology.
[33] S. Johnston,et al. Mycobacterial Bacilli Are Metabolically Active during Chronic Tuberculosis in Murine Lungs: Insights from Genome-Wide Transcriptional Profiling , 2007, Journal of bacteriology.
[34] J. Mckinney,et al. Microbial phenotypic heterogeneity and antibiotic tolerance. , 2007, Current opinion in microbiology.
[35] L. Silver. Multi-targeting by monotherapeutic antibacterials , 2007, Nature Reviews Drug Discovery.
[36] G. Ippolito,et al. Isoniazid prophylaxis differently modulates T-cell responses to RD1-epitopes in contacts recently exposed to Mycobacterium tuberculosis: a pilot study , 2007, Respiratory research.
[37] D. Pompliano,et al. Drugs for bad bugs: confronting the challenges of antibacterial discovery , 2007, Nature Reviews Drug Discovery.
[38] D. Kirschner,et al. Contribution of CD8+ T cells to control of Mycobacterium tuberculosis infection. , 2006, The Journal of Immunology.
[39] J. Deeks,et al. Dynamic antigen-specific T-cell responses after point-source exposure to Mycobacterium tuberculosis. , 2006, American journal of respiratory and critical care medicine.
[40] R. Sauermann,et al. Principles of Antibiotic Penetration into Abscess Fluid , 2006, Pharmacology.
[41] A. Myers,et al. Early Events in Mycobacterium tuberculosis Infection in Cynomolgus Macaques , 2006, Infection and Immunity.
[42] E. Muñoz-Elías,et al. Role of the methylcitrate cycle in Mycobacterium tuberculosis metabolism, intracellular growth, and virulence , 2006, Molecular microbiology.
[43] R. Wilkinson,et al. Effect of treatment of latent tuberculosis infection on the T cell response to Mycobacterium tuberculosis antigens. , 2006, The Journal of infectious diseases.
[44] D. Eisenberg,et al. Unique Transcriptome Signature of Mycobacterium tuberculosis in Pulmonary Tuberculosis , 2006, Infection and Immunity.
[45] J. Norton,et al. Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[46] J. Dannenberg. Pathogenesis of Human Pulmonary Tuberculosis: Insights from the Rabbit Model , 2006 .
[47] E. Rubin,et al. Differential Antibiotic Susceptibilities of Starved Mycobacterium tuberculosis Isolates , 2005, Antimicrobial Agents and Chemotherapy.
[48] J. Kettenbach,et al. Antibiotic Abscess Penetration: Fosfomycin Levels Measured in Pus and Simulated Concentration-Time Profiles , 2005, Antimicrobial Agents and Chemotherapy.
[49] Nagasuma R. Chandra,et al. Flux Balance Analysis of Mycolic Acid Pathway: Targets for Anti-Tubercular Drugs , 2005, PLoS Comput. Biol..
[50] M. Reed,et al. Virulence of selected Mycobacterium tuberculosis clinical isolates in the rabbit model of meningitis is dependent on phenolic glycolipid produced by the bacilli. , 2005, The Journal of infectious diseases.
[51] C. F. von Reyn,et al. High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[52] A. Garza,et al. The relA Homolog of Mycobacterium smegmatis Affects Cell Appearance, Viability, and Gene Expression , 2005, Journal of bacteriology.
[53] P. Venkatesan,et al. Bactericidal Action of Gatifloxacin, Rifampin, and Isoniazid on Logarithmic- and Stationary-Phase Cultures of Mycobacterium tuberculosis , 2005, Antimicrobial Agents and Chemotherapy.
[54] Pam Sonnenberg,et al. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. , 2005, The Journal of infectious diseases.
[55] Hinrich W. H. Göhlmann,et al. A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis , 2005, Science.
[56] V. Mischenko,et al. Direct comparison of low-dose and Cornell-like models of chronic and reactivation tuberculosis in genetically susceptible I/St and resistant B6 mice. , 2005, Tuberculosis.
[57] T. Myers,et al. The Transcriptional Responses of Mycobacterium tuberculosis to Inhibitors of Metabolism , 2004, Journal of Biological Chemistry.
[58] Byron F. Brehm-Stecher,et al. Single-Cell Microbiology: Tools, Technologies, and Applications , 2004, Microbiology and Molecular Biology Reviews.
[59] Georg E. Schulz,et al. The Structure of a Mycobacterial Outer-Membrane Channel , 2004, Science.
[60] D. Saini,et al. Disruption of response regulator gene, devR, leads to attenuation in virulence of Mycobacterium tuberculosis. , 2004, FEMS microbiology letters.
[61] Gilla Kaplan,et al. Differential expression of iron-, carbon-, and oxygen-responsive mycobacterial genes in the lungs of chronically infected mice and tuberculosis patients , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[62] Christopher M. Sassetti,et al. Genetic requirements for mycobacterial survival during infection , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[63] JoAnne L. Flynn,et al. Experimental Mycobacterium tuberculosis Infection of Cynomolgus Macaques Closely Resembles the Various Manifestations of Human M. tuberculosis Infection , 2003, Infection and Immunity.
[64] Tsuneo Suzuki,et al. Uptake rates of 18F-fluorodeoxyglucose and 11C-choline in lung cancer and pulmonary tuberculosis: a positron emission tomography study. , 2003, Chest.
[65] Dirk Schnappinger,et al. Inhibition of Respiration by Nitric Oxide Induces a Mycobacterium tuberculosis Dormancy Program , 2003, The Journal of experimental medicine.
[66] Chi-Ming Lee,et al. Intense uptake of [F-18]-fluoro-2 deoxy-d-glucose in active pulmonary tuberculosis , 2003, Annals of nuclear medicine.
[67] E. Rubin,et al. Genes required for mycobacterial growth defined by high density mutagenesis , 2003, Molecular microbiology.
[68] C. Walsh. Antibiotics: Actions, Origins, Resistance , 2003 .
[69] G. Schoolnik,et al. Transcriptional adaptation of Mycobacterium tuberculosis within macrophages: Insights into the phagosomal environment JOURNAL OF EXPERIMENTAL MEDICINE , 2003 .
[70] J. Betts,et al. In Situ Detection of Mycobacterium tuberculosis Transcripts in Human Lung Granulomas Reveals Differential Gene Expression in Necrotic Lesions , 2002, Infection and Immunity.
[71] Thomas M. Shinnick,et al. Microarray Analysis of the Mycobacterium tuberculosis Transcriptional Response to the Acidic Conditions Found in Phagosomes , 2002, Journal of bacteriology.
[72] Gary K. Schoolnik,et al. ideR, an Essential Gene in Mycobacterium tuberculosis: Role of IdeR in Iron-Dependent Gene Expression, Iron Metabolism, and Oxidative Stress Response , 2002, Infection and Immunity.
[73] Joseph Keane,et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent , 2001 .
[74] J. Keane,et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. , 2001, The New England journal of medicine.
[75] James C. Sacchettini,et al. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase , 2000, Nature.
[76] J. Goo,et al. Pulmonary tuberculoma evaluated by means of FDG PET: findings in 10 cases. , 2000, Radiology.
[77] I. Orme,et al. Progression of chronic pulmonary tuberculosis in mice aerogenically infected with virulent Mycobacterium tuberculosis. , 1997, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[78] J. Liu,et al. Mycolic Acid Structure Determines the Fluidity of the Mycobacterial Cell Wall* , 1996, The Journal of Biological Chemistry.
[79] P. Venkatesan,et al. Bactericidal action of ofloxacin, sulbactam-ampicillin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis , 1996, Antimicrobial agents and chemotherapy.
[80] W. Stead. Management of Health Care Workers after Inadvertent Exposure to Tuberculosis: A Guide for the Use of Preventive Therapy , 1995, Annals of Internal Medicine.
[81] L. Wayne,et al. Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis , 1994, Antimicrobial Agents and Chemotherapy.
[82] H. Nikaido,et al. Permeability of the mycobacterial cell wall. , 1991, Research in microbiology.
[83] J. Grange. The mycobacteria: a sourcebook , 1985 .
[84] Kislitsyna Na. Comparative evaluation of rifampicin and isoniazid penetration into the pathological foci of the lungs in tuberculosis patients , 1985 .
[85] N. A. Kislitsyna. [Comparative evaluation of rifampicin and isoniazid penetration into the pathological foci of the lungs in tuberculosis patients]. , 1985, Problemy tuberkuleza.
[86] G. Kubica,et al. The Mycobacteria : a sourcebook , 1984 .
[87] Kislitsyna Na,et al. Rifampicin and isoniazid concentration in the blood and resected lungs in tuberculosis with combined use of the preparations , 1980 .
[88] N. A. Kislitsyna,et al. [Rifampicin and isoniazid concentration in the blood and resected lungs in tuberculosis with combined use of the preparations]. , 1980, Problemy tuberkuleza.
[89] D. Snider,et al. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies. , 2015, The American review of respiratory disease.
[90] S. Robbins,et al. Pathologic basis of disease , 1974 .
[91] R. Parrot,et al. [Rifomycin levels in the lung and tuberculous lesions in man]. , 1969, Acta tuberculosea et pneumologica Belgica.
[92] Veening Gj. Long term isoniazid prophylaxis. Controlled trial on INH prophylaxis after recent tuberculin conversion in young adults. , 1968 .
[93] G. Veening. Long term isoniazid prophylaxis. Controlled trial on INH prophylaxis after recent tuberculin conversion in young adults. , 1968, Bulletin of the International Union against Tuberculosis.
[94] S. Ferebee,et al. A CONTROLLED TRIAL OF ISONIAZID PROPHYLAXIS IN MENTAL INSTITUTIONS. , 1963, The American review of respiratory disease.
[95] S. Ferebee,et al. Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts. , 2015, The American review of respiratory disease.
[96] W. Segal,et al. Pathogenic and immunogenic differentiation of Mycobacterium tuberculosis grown in vitro and in vivo. , 1957, American review of tuberculosis.
[97] W. Segal,et al. BIOCHEMICAL DIFFERENTIATION OF MYCOBACTERIUM TUBERCULOSIS GROWN IN VIVO AND IN VITRO , 1956, Journal of bacteriology.
[98] H. M. Vandiviere,et al. THE TREATED PULMONARY LESION AND ITS TUBERCLE BACILLUS.*: II. THE DEATH AND RESURRECTION , 1956, The American journal of the medical sciences.